Who we are BioArt Cultivation
We invest in ongoing research to understand the full therapeutic potential of cannabis, its interactions with other medications, and possible long-term effects. This research will lead to improved treatment guidelines and patient care.
BioArt Cultivation uses a patented, recognized method to produce high-quality CBD products for wholesale and retail, including white-label solutions and the development of new projects in the field of edible CBD products.
Our wide range of products includes CBD flowers, CBD cuttings, CBD oils, waxes, distillates, CBD isolates with controlled active ingredient content and medicinal THC.
Our technology is fully GMP-compliant, highly productive and delivers quality at the highest level - while being completely sustainable and waste-free.
We take into account the social and economic impacts of medical cannabis, including the creation of new jobs, potential tax revenues, and the effects on the community.
Together we combine expertise, innovation and market knowledge. Bioart Cultivation works with strong partners such as TB Farming (strategy & production), Premium Chronic (own retail brand) and Metawise (marketing & business development)
Step by step to the Harvest
We are building a business model that does not rely solely on quick returns or a sale to a larger company.
Instead, we strive to establish a sustainable and long-term profitable operation.
Innovation and Adaptation
Continuous innovation and adaptability are essential for us — whether in response to changes in the regulatory landscape, new scientific findings, or market needs.
This includes:
Production plant
GMP standard
For every business idea
CBD products for wholesale, retail and white label projects
Since 2021
we set standards in quality and innovation
CBD flower production
Towards medical THC
Expansion of the production plant
Partnership with TB Farming
Retail brand Premium Chronic
SocialResponsibility
We take responsibility in society by building close relationships with local communities, both in terms of production and patient access.
This should lead to a stronger sense of social responsibility and long-term trust.







